GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:003133035 | Thyroid | ATC | negative regulation of cellular catabolic process | 136/6293 | 262/18723 | 6.47e-10 | 1.71e-08 | 136 |
GO:000989529 | Thyroid | ATC | negative regulation of catabolic process | 159/6293 | 320/18723 | 1.61e-09 | 3.99e-08 | 159 |
GO:003166927 | Thyroid | ATC | cellular response to nutrient levels | 112/6293 | 215/18723 | 1.57e-08 | 3.20e-07 | 112 |
GO:003166827 | Thyroid | ATC | cellular response to extracellular stimulus | 125/6293 | 246/18723 | 1.65e-08 | 3.31e-07 | 125 |
GO:004259424 | Thyroid | ATC | response to starvation | 103/6293 | 197/18723 | 4.59e-08 | 8.31e-07 | 103 |
GO:000926724 | Thyroid | ATC | cellular response to starvation | 85/6293 | 156/18723 | 6.14e-08 | 1.09e-06 | 85 |
GO:0031667210 | Thyroid | ATC | response to nutrient levels | 212/6293 | 474/18723 | 2.37e-07 | 3.70e-06 | 212 |
GO:0016358110 | Thyroid | ATC | dendrite development | 119/6293 | 243/18723 | 4.65e-07 | 6.75e-06 | 119 |
GO:003090015 | Thyroid | ATC | forebrain development | 164/6293 | 379/18723 | 4.85e-05 | 3.87e-04 | 164 |
GO:002153712 | Thyroid | ATC | telencephalon development | 113/6293 | 248/18723 | 5.61e-05 | 4.32e-04 | 113 |
GO:002154312 | Thyroid | ATC | pallium development | 81/6293 | 169/18723 | 7.67e-05 | 5.80e-04 | 81 |
GO:003563322 | Thyroid | ATC | maintenance of blood-brain barrier | 22/6293 | 35/18723 | 3.74e-04 | 2.28e-03 | 22 |
GO:003526414 | Thyroid | ATC | multicellular organism growth | 61/6293 | 132/18723 | 1.73e-03 | 8.66e-03 | 61 |
GO:004505621 | Thyroid | ATC | transcytosis | 14/6293 | 21/18723 | 1.99e-03 | 9.54e-03 | 14 |
GO:003030719 | Thyroid | ATC | positive regulation of cell growth | 74/6293 | 166/18723 | 2.06e-03 | 9.73e-03 | 74 |
GO:004863815 | Thyroid | ATC | regulation of developmental growth | 136/6293 | 330/18723 | 2.17e-03 | 1.02e-02 | 136 |
GO:000657522 | Thyroid | ATC | cellular modified amino acid metabolic process | 82/6293 | 188/18723 | 2.60e-03 | 1.20e-02 | 82 |
GO:0021766 | Thyroid | ATC | hippocampus development | 38/6293 | 80/18723 | 6.84e-03 | 2.72e-02 | 38 |
GO:004592720 | Thyroid | ATC | positive regulation of growth | 106/6293 | 259/18723 | 7.90e-03 | 3.06e-02 | 106 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FSD2 | SNV | Missense_Mutation | rs200109394 | c.1411N>T | p.Pro471Ser | p.P471S | A1L4K1 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
FSD2 | SNV | Missense_Mutation | | c.413N>T | p.Gly138Val | p.G138V | A1L4K1 | protein_coding | deleterious(0.04) | benign(0.348) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FSD2 | SNV | Missense_Mutation | rs774888742 | c.1499N>T | p.Ser500Leu | p.S500L | A1L4K1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
FSD2 | SNV | Missense_Mutation | | c.923C>A | p.Thr308Lys | p.T308K | A1L4K1 | protein_coding | deleterious(0.01) | benign(0.435) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
FSD2 | SNV | Missense_Mutation | rs781225191 | c.388G>A | p.Glu130Lys | p.E130K | A1L4K1 | protein_coding | tolerated(0.07) | benign(0.096) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
FSD2 | SNV | Missense_Mutation | novel | c.493N>T | p.Val165Phe | p.V165F | A1L4K1 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
FSD2 | SNV | Missense_Mutation | | c.520N>A | p.Glu174Lys | p.E174K | A1L4K1 | protein_coding | tolerated(0.07) | possibly_damaging(0.867) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FSD2 | SNV | Missense_Mutation | | c.1398G>A | p.Met466Ile | p.M466I | A1L4K1 | protein_coding | tolerated(0.05) | benign(0.003) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FSD2 | SNV | Missense_Mutation | | c.88G>A | p.Glu30Lys | p.E30K | A1L4K1 | protein_coding | tolerated(0.41) | benign(0.006) | TCGA-VS-A8QC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | PD |
FSD2 | SNV | Missense_Mutation | novel | c.586N>A | p.Glu196Lys | p.E196K | A1L4K1 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |